A Phase I/II, Open-Label, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (MA09-hRPE) Cells in Patients With Geographic Atrophy Secondary to Myopic Macular Degeneration

Trial Profile

A Phase I/II, Open-Label, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (MA09-hRPE) Cells in Patients With Geographic Atrophy Secondary to Myopic Macular Degeneration

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 20 Jul 2016

At a glance

  • Drugs MA09 retinal pigment epithelial cell replacement therapy-Advanced Cell Technology (Primary)
  • Indications Degenerative myopia
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Jul 2016 Status changed from recruiting to withdrawn prior to enrolment.
    • 05 Feb 2016 Planned End Date changed from 1 Apr 2015 to 1 Dec 2017, according to ClinicalTrials.gov record.
    • 05 Feb 2016 Planned primary completion date changed from 1 Apr 2015 to 1 Dec 2017, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top